Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial symbols : Pstv save search
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 2.96%
H: 0.57%
C: -7.47%
trial therapeutics plus
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
Published: 2023-11-20 (Crawled : 12:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: -15.59%
H: 12.61%
C: -14.41%
meeting trial therapeutics plus
Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases
Published: 2023-10-10 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 6.39%
H: 0.0%
C: -1.26%
trial therapeutics plus
Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase
Published: 2023-09-05 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: -1.07%
H: 2.17%
C: -1.44%
trial therapeutics plus
Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference
Published: 2023-08-11 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 5.33%
H: 0.0%
C: -20.89%
conference cancer trial therapeutics plus
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
Published: 2023-08-08 (Crawled : 15:20) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 1.53%
H: 8.3%
C: -0.38%
conference cancer trial therapeutics plus
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
Published: 2023-06-29 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 1.92%
H: 7.55%
C: -7.17%
positive trials meeting therapeutics plus
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
Published: 2023-05-02 (Crawled : 11:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.1%
H: 0.96%
C: -1.26%
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 2.01%
H: 0.0%
C: -9.09%
pharma drug ongoing trials solutions collaboration therapeutics plus
Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
Published: 2023-04-19 (Crawled : 12:20) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: -1.14%
H: 22.39%
C: 4.39%
trial therapeutics plus
Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases
Published: 2023-04-18 (Crawled : 12:20) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: -0.11%
H: 5.28%
C: 3.8%
trial therapeutics plus
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
Published: 2023-03-28 (Crawled : 12:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: -2.68%
trial therapeutics plus phase 1
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal MetastasesFirst data readout of Phase 1/Part A trial expected second half of 2023
Published: 2023-03-22 (Crawled : 12:00) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
expected readout trial therapeutics plus phase 1
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
Published: 2023-03-22 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.12%
H: 1.39%
C: 0.0%
trial therapeutics plus phase 1
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Published: 2023-01-18 (Crawled : 12:20) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 3.23%
H: 0.0%
C: -6.25%
treatment trial therapeutics plus phase 2b glioblastoma
Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Published: 2022-11-19 (Crawled : 16:20) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
| Email alert
Add to watchlist
day trials education meeting therapeutics plus
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
Published: 2022-10-19 (Crawled : 11:00) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 2.04%
H: 0.0%
C: -2.44%
nuclear trial therapeutics plus
Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine
Published: 2022-10-04 (Crawled : 12:00) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 0.68%
H: 10.11%
C: 4.63%
ongoing trials nuclear therapeutics plus
Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 1.48%
H: 22.86%
C: 8.56%
trial therapeutics plus
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
Published: 2022-08-13 (Crawled : 20:20) - globenewswire.com
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
| Email alert
Add to watchlist
ongoing trials conference therapeutics plus positive train brain metastases
Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
Published: 2022-07-28 (Crawled : 14:00) - biospace.com/
PSTV | News | $1.55 -4.91% -5.16% 8.4K
|
Health Technology
|
| O: 5.53%
H: 7.26%
C: -3.64%
ongoing trials conference therapeutics plus train brain metastases
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.